对BRAF抑制剂耐药性的转子子子介导功能基因组查揭示了汇聚的Hippo和MAPK通路激活事件
Li Chen1, Iulian Pruteanu-Malinici2,3, Anahita Dastur2,4
1Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA, 02129, USA. lichenboston@gmail.com.
Scientific reports
|January 24, 2025
概括
针对性黑色素瘤治疗,如BRAF抑制剂,面临药物耐药性. 这项研究确定了关键的抵抗基因和机制,包括河马通路,提供了克服治疗障碍的潜在策略.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- BRAF抑制剂对BRAF突变黑色素瘤有效,但耐药性限制了它们的成功.
- 识别耐药性机制对于改善向癌症疗法至关重要.
研究的目的:
- 用 piggyBac 转位子激活突变发生屏幕在黑色素瘤中识别对 BRAF 抑制产生抗性的基因.
- 阐明抵抗机制的功能多样性,并确定涉及的关键途径.
主要方法:
- 在黑色素瘤中使用 piggyBac 转位子激活突变发生屏幕来识别耐药基因.
- 对抗性基因进行了整合性分析,以确定功能多样性.
- 研究了Hippo通路效应器TAZ在抵抗中介作用的作用.
主要成果:
- 确定了赋予抗BRAF抑制的抗性基因.
- 揭示了抵抗机制汇聚在有限数量的途径上,包括MAPK,PI3K-AKT和Hippo途径.
- 通过转录调节和与NEDD4L的相互作用来证明TAZ在BRAF抑制抵抗中的关键作用.
结论:
- 一套有限的治疗策略可以克服由大量基因组介导的耐药性.
- 河马通路,特别是TAZ,是黑色素瘤中BRAF抑制抵抗的关键调解者.
- 向TAZ和相关途径可能为BRAF突变黑色素瘤提供新的治疗途径.
更多相关视频
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
6.9K
10:13A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
11.1K
相关概念视频
MAPK Signaling Cascades
5.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.3K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
